Metabolic studies on cannabinoids presented at ICRS 2008

28 June 2008

Mike Cawthorne, Director of Metabolic Research at the Clore Laboratory, University of Buckingham, UK, gave a talk entitled ‘The metabolic effects of tetrahydrocannabivarin (THCV) and cannabidiol (CBD)’ at ICRS 2008, The 18th Annual Symposium of the International Cannabinoid Research Society, held 26–29 June 2008 in Aviemore, Scotland.

Mike reported on studies done by Mohamed Zaïbi and Ed Wargent in the Clore Laboratory in conjunction with GW Pharmaceuticals. These studies showed that tetrahydrocannabivarin acted as a CB-1 receptor antagonist in vivo and that cannabidiol reduced total plasma cholesterol whilst increasing HDL cholesterol. It also reduced hepatic steatosis.